Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

Abstract Objectives The primary objective of MATIS is to determine the efficacy of ruxolitinib (RUX) or fostamatinib (FOS) compared to standard of care (SOC) with respect to reducing the proportion of hospitalised patients progressing from mild or moderate to severe COVID-19 pneumonia. Secondary obj...

Full description

Bibliographic Details
Main Authors: Nikhil Vergis, Rachel Phillips, Victoria Cornelius, Alexia Katsarou, Taryn Youngstein, Lucy Cook, Michelle Willicombe, Clio Pilay, Tina Shturova, Melanie Almonte, Asad Charania, Richard Turner, Onn Min Kon, Graham Cooke, Mark Thursz, Svetlana Cherlin, James Wason, Dragana Milojkovic, Andew J. Innes, Nichola Cooper
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Trials
Subjects:
COVID-19
coronavirus
randomised controlled trial
protocol
pneumonia
fostamatinib
Online Access:https://doi.org/10.1186/s13063-021-05190-z

Internet

https://doi.org/10.1186/s13063-021-05190-z

Similar Items